Benjamin F. Edwards & Company, Inc. Argenx Se Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Argenx Se stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 164 shares of ARGX stock, worth $89,045. This represents 0.0% of its overall portfolio holdings.
Number of Shares
164
Previous 161
1.86%
Holding current value
$89,045
Previous $63,000
12.7%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARGX
# of Institutions
371Shares Held
31.4MCall Options Held
303KPut Options Held
429K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.04 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$1.91 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.34 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.05 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$821 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $30B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...